Intensity Therapeutics, Inc. (Nasdaq: INTS), a biotechnology company specializing in the development of immune-based intratumoral cancer therapies, announced that its product INT230-6 achieved a 100% complete response rate in preclinical models of Malignant Peripheral Nerve Sheath Tumors (MPNST). The study was conducted in collaboration with the Staedtke-Bai laboratory at Johns Hopkins University. Over a period of 21 days, all animals treated with INT230-6 in the study achieved complete responses, while tumors in the control group continued to grow. These results have been presented and mark the first instance of INT230-6 being used on a neurological-specific tumor, with plans for further preclinical research on other neurological cancer models.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.